Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13169700 | 0.90 | ALDH1A1 (0.49) | SYKALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL13169696 | 0.89 | NPC1 (0.51) | ALDH1A1MAPTHPGDSMN1; SMN2OPRM1 | |
| SCHEMBL13169901 | 0.85 | EGFR (0.58) | SYKEGFRJAK3BTK | |
| SCHEMBL13169701 | 0.82 | SYK (0.62) | SYKEGFR | |
| SCHEMBL13169818 | 0.79 | JAK2 (0.58) | SYKJAK2EGFRHDAC1BTK | |
| SCHEMBL13169900 | 0.76 | EGFR (0.55) | SYKEGFRJAK3BTK | |
| SCHEMBL13170155 | 0.74 | SYK (0.46) | SYKJAK2EGFRNPC1MITF | |
| SCHEMBL13169817 | 0.74 | EGFR (0.63) | JAK2EGFRHDAC1BTK | |
| SCHEMBL13169906 | 0.73 | EGFR (0.60) | EGFRJAK3BTK | |
| SCHEMBL13169915 | 0.73 | BTK (0.56) | EGFRJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040549-B2 | Thiopyrimidine-based compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040549-B2 | Thiopyrimidine-based compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8846704-B2 | Thiopyrimidine-based compounds and uses thereof | YM Biosciences Austraila Pty Ltd (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846704-B2 | Thiopyrimidine-based compounds and uses thereof | YM Biosciences Austraila Pty Ltd (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD | 2010-09-23 | — | — | US | disclosed |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | SYK 252/4885ALDH1A1 1850/4885MAPT 3933/4885 |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | SYK 252/4885ALDH1A1 1850/4885MAPT 3933/4885 |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | SYK 252/4885ALDH1A1 1850/4885MAPT 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.